Actemra 162 mg PFS is oral and small molecule medicine belongs to JAK inhibitors used for the treatment of Rheumatoid Arthritis in adults who were not responded well with other RA medications. It is also approved treatment for Psoriatic Arthritis and Ulcerative Colitis due to it's immunosuppressant property. It should not be use with other biologics or immunosuppressants. It is long term treatment so continue it on regular basis even if you don't find any visible relief in your condition. Do not double your dose even on you missed the scheduled dose. Actemra 162 mg PFS can not be started if, Rheumatoid arthritis is not active or you haven't tried other treatment options available for such condition. One should avoid taking Actemra 162 mg PFS if patient is lactose intolerant. Safety is not established in pregnant women and lactating mother. Inform your health care provider if other medical conditions co-exist like renal impairment, hepatic impairment, recurrent infections, or other vascular disorders.
Actemra 162 mg PFS provides relief in pain, swelling and joint tenderness resulted from rheumatoid arthritis and psoriatic arthritis. Actemra 162 mg PFS also gives response in patients who doesn't responded well with other Disease-modifying antirheumatic drugs (DMARDs)
Actemra 162 mg PFS is taken Orally with or without food. Usually taken two tablets a day or as per your doctor's consultation.
Actemra 162 mg PFS primarily inhibits the Janus Kinase(JAK) Enzymes which are group of Intracellular Enzymes responsible for Immune Cell function. Therapeutically it blocks JAK-STAT pathway to minimize the inflammatory response that ultimately leads to immunosuppression.